Dose: 5 mg
Single Dose: 5 (5)
Frequency: As recommended.
Route: IV
Instructions: Once a day injected in vein for 10-14 days.

Dose: 2.5 to 5 mg
Single Dose: 3.8 (3.75)
Frequency: As recommended.
Route: IV
Instructions: IV Injection for 10-14 days due to higher CD3 lymphocytes count the dose required to be titrated upw

. It is of Natural origin and belongs to Moco-clonal antibody murine. . The Molecular Weight of Muromonab-cd3 is 150000.00.

Muromonab-cd3 is contraindicated in conditions like Hypertension,Fever,Hypersensitivity to the drug.

The signs and symptoms that are produced after the acute overdosage of Muromonab-cd3 include Pulmonary edema, Convulsions, Seizures, Hallucinations, Cardiac arrest, Trembling, Bruising.The symptomatic adverse reactions produced by Muromonab-cd3 are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Diarrhea, Fever, Chills, Tremor, Nausea and vomiting, Faintness, Rigors, GI bleeding, Oedema, dizziness, faintness.

Muromonab-cd3 is primarily indicated in conditions like Graft rejection, Graft versus host disease.

Muromonab-cd3 is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementCyclosporin ALikely interaction of MUROMONAB CD3 increasing the SERUM LEVEL of CYCLOSPORIN. IndomethacinLikely interaction of INDOMETHACIN increasing the CNS TOXICITY of MUROMONAB CD3. Mumps VaccineConcurrent use may weaken the immune system. These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Drug should not be given to Paediatrics, Pregnant Mothers, Cardiac / Hypertensive Patients, patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Prescribing should be kept to a minimum in all patients with severe liver disease, especially if jaundice, ascites, or evidence of encephalopathy present. Patient temperature should not exceed 37.8°C (100°F) at time of administration. Severe pulmonary edema has occurred in patients with fluid overload. May result in an increased susceptibility to infection; dosage of concomitant immunosuppressants should be reduced during Muromonab-cd3 therapy; cyclosporine should be decreased to 50% usual maintenance dose and maintenance therapy resumed about 4 days before stopping Muromonab-cd3.